The Use of Photodynamic Therapy for Head, Neck, and Brain Diseases

• Published in: International journal of molecular sciences Vol. 24; no. 14; p. 11867
• Main Authors: Domka, Wojciech, Bartusik-Aebisher, Dorota, Mytych, Wiktoria, Dynarowicz, Klaudia, Aebisher, David
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-07-2023; MDPI
• Subjects: Active oxygen; Apoptosis; Boron; Brain cancer; Brain research; brain tumor; Brain tumors; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Drug delivery systems; Drug dosages; Drugs; Etiology; Head & neck cancer; head diseases; Health aspects; Hypoxia; Larynx; Lifestyles; Light; Medical prognosis; Metastasis; neck diseases; Necrosis; Neutrons; Oncology, Experimental; Outdoor air quality; Photochemotherapy; Photodynamic therapy; Radiation; Review; Squamous cell carcinoma; Toxicity; treatment; Tumors; Vehicles; Poland; treatment; brain tumor; neck diseases; head diseases; photodynamic therapy
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms241411867

Head-neck cancers as a group have the 7th highest rate of incidence worldwide. The most often diagnosed disease of the head and neck is squamous cell carcinoma (90% of cases). Another specific group of tumors is brain tumors. These can be divided into primary tumors and secondary tumors associated with metastasis. Research shows that treating head and neck cancers continues to be problematic and challenging, and researchers are actively seeking new treatments that would improve survival rates and reduce side effects. Irradiation of tumor tissue with the optimal wavelength of light in photodynamic therapy (PDT) generates predominantly singlet oxygen in tissue-based photosensitizers (PSs) or reactive oxygen radicals in the case of vascular PSs leading to cellular apoptosis and necrosis. A very important feature of PDT is that cells cannot become immune to the effects of singlet oxygen or reactive oxygen radicals. However, photosensitizer (PS) transport is influenced by the specific structures of cancer tumors and the concentration of PS decreases in cells far from the vessel lumen. Therefore, PSs may not reach tumor interiors, which decreases therapy effectiveness. The use of drug carriers and 3rd generation PSs that contain biocompatible functional groups makes it possible to control transport. This review of the current literature on PDT was conducted through databases such as PubMed and Scopus. The types of publications considered included clinical studies and most of the articles included were published in English. Based on the publications collected, we conclude that researchers have demonstrated the potential of PDT as a therapeutic platform for head, neck, and brain diseases.